JP2362

JP2362 is a synthetic, truncated analog of the marine natural product diazonamide A, developed by Joyant Pharmaceuticals. It functions as a potent anti-mitotic agent that induces G2/M cell cycle arrest. In preclinical rodent models, JP2362 demonstrated a therapeutic window more than 20-fold larger than traditional anti-mitotic drugs like taxanes and vinca alkaloids. It has shown significant efficacy in various tumor models, including pancreatic cancer xenografts, while exhibiting minimal systemic toxicity at efficacious doses. The compound was designed to simplify the complex structure of natural diazonamide A while maintaining or improving its pharmacological profile.

Other names

diazonamide analog